Incyte and Oxagen Launch Osteoporosis Genetics Program

Jan 29, 2001

NEW YORK, Jan 29 - Incyte and UK-based Oxagen have announced a collaboration, in which the two companies will jointly investigate genes related to osteoporosis for drug target validation and discovery, and Oxagen will receive access to Incyte’s LifeSeq gold database for use in its disease areas, the companies announced Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in PNAS

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

Choice Against Testing

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

Call for Gene Editing Oversight

The Japan Times says regulations are needed to oversee human genome-editing research.

This Week in PLOS

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Main menu